Help Ensure the Safe Use of Secondary Hyperparathyroid Meds
The new med etelcalcetide (Parsabiv, PAR-sah-biv) will raise questions about treating hyperparathyroidism in dialysis patients.
Hyperphosphatemia and low vitamin D in renal patients leads to hypocalcemia...which stimulates parathyroid hormone (PTH) release.
This is why the first steps in treating patients with elevated PTH are to control high phosphate and treat vitamin D deficiency.
Get unlimited access through an Enterprise license
Hospital Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Not sold to individuals